Drug Trial Radar · NCT04585815
Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced Non-small Cell Lung Cancer (NSCLC) (Landscape 1011 Study)
Last checked: Nov 19, 2026Latest source record: Jan 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
34
Actual
Start
Nov 10, 2020
Primary completion
May 17, 2023
Study completion Oct 29, 2024
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Oct 14, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Phase 1b/Phase 2 Umbrella Study; open-label, multi-center, parallel group study. Sasanlimab (a PD-1 antagonist monoclonal antibody) will be combined with a different targeted therapy in each sub-study. Phase1b of each sub-study will evaluate the safety of the combination and select the dose for the Phase 2 portion. Phase 2 of each sub-study will evaluate the anti-tumor activity of the combination. Sub-Study A is active, not recruiting, ongoing participants are still receiving treatment in Phase 1, Phase 2 will not be initiated. Sub-study B is complete. All participants have discontinued treatment and any additional follow up required by protocol.
Conditions
- Carcinoma, Non-Small-Cell Lung
Interventions
Sasanlimab Prefilled syringeDrug
prefilled syringe
EncorafenibDrug
capsules
BinimetinibDrug
tablets
SasanlimabDrug
solution supplied in vials
AxitinibDrug
tablets
SEA-TGTDrug
solution in vials
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1b of Sub-Study A: Percentage of Participants With Dose-Limiting Toxicities (DLT)Time frame: Day 1 up to Day 28 of Cycle 1
- Phase 2 of Sub-Study A: Durable Objective Response Rate (ORR)Time frame: From the date of first CR or PR until the date of the first documentation of PD, death, or start of new anticancer therapy
- Phase 1b of Sub-Study B: Percentage of Participants With DLTTime frame: Day 1 up to Day 21 of Cycle 1
- Phase 2 Sub-Study B: Objective Response RateTime frame: From the date of first CR or PR until the date of the first documentation of PD, death, or start of new anticancer therapy (maximum of 21 months)
Locations
55 sites in 4 countries. Site status is shown where the registry gives one.
City of Hope Investigational Drug Services (IDS)
Duarte, California
City of Hope
Duarte, California
UCSD Medical Center - Encinitas
Encinitas, California
California Cancer Associates for Research and Excellence, Inc (cCARE)
Fresno, California
The Oncology Institute of Hope and Innovation
Glendale, California
Koman Family Outpatient Pavilion
La Jolla, California
Sulpizio Cardiovascular Center at UC San Diego Health
La Jolla, California
UC San Diego Medical Center - La Jolla (Jacobs Medical Center / Thornton Pavilion)
La Jolla, California
UC San Diego Moores Cancer Center - Investigational Drug Services
La Jolla, California
UCSD Perlman Medical Offices
La Jolla, California
UC San Diego Moores Cancer Center
La Jolla, California
The Oncology Institute of Hope and Innovation
Long Beach, California
The Oncology Institute of Hope and Innovation
Los Angeles, California
USC/Norris Comprehensive Cancer Center
Los Angeles, California
UC San Diego Medical Center - Hillcrest
San Diego, California
The Oncology Institute of Hope and Innovation
Santa Ana, California
UCSD Medical Center - Vista
Vista, California
The Oncology Institute of Hope and Innovation
Whittier, California
AdventHealth Celebration Infusion Center
Celebration, Florida
AdventHealth Medical Group Oncology Research at Celebration
Celebration, Florida
Advent Health Orlando - Investigational Drug Services
Orlando, Florida
AdventHealth Orlando Infusion Center
Orlando, Florida
AdventHealth Orlando
Orlando, Florida
Moffitt Cancer Center
Tampa, Florida
Henry Ford Medical Center - Fairlane
Dearborn, Michigan
Henry Ford Hospital
Detroit, Michigan
Henry Ford Medical Center - Columbus
Novi, Michigan
Icahn School of Medicine at Mount Sinai
New York, New York
Mount Sinai Hospital Pharmacy
New York, New York
Tennessee Oncology PLLC
Dickson, Tennessee
Tennessee Oncology PLLC
Franklin, Tennessee
Tennessee Oncology PLLC
Gallatin, Tennessee
Tennessee Oncology PLLC
Hendersonville, Tennessee
Tennessee Oncology PLLC
Hermitage, Tennessee
Tennessee Oncology PLLC
Lebanon, Tennessee
Tennessee Oncology PLLC
Murfreesboro, Tennessee
Sarah Cannon Research Institute - Pharmacy
Nashville, Tennessee
Tennessee Oncology PLLC
Nashville, Tennessee
Tennessee Oncology PLLC
Nashville, Tennessee
Tennessee Oncology PLLC
Nashville, Tennessee
Showing 40 of 55 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.